Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

25P - Circulating tumor DNA is predictive of overall survival in patients with metastatic uveal melanoma

Date

12 Dec 2024

Session

Poster Display session

Presenters

Egle Ramelyte

Citation

Annals of Oncology (2024) 24 (suppl_1): 1-16. 10.1016/iotech/iotech100742

Authors

E. Ramelyte1, J. Kött2, A. Lawless3, A. Ciernik4, S. Schneider2, S. Freiberger5, S. Orjuela5, R. Dummer4, R. Sullivan6, M.P. Levesque7, C. Gebhardt2

Author affiliations

  • 1 Zurich/CH
  • 2 University Medical Center Hamburg-Eppendorf, Hamburg/DE
  • 3 Massachusetts General Hospital, Boston/US
  • 4 University Hospital Zürich, Zurich/CH
  • 5 Oncobit AG, Schlieren/CH
  • 6 Massachusetts General Hospital Cancer Center, Boston/US
  • 7 USZ - University Hospital Zürich, Zurich/CH

Resources

This content is available to ESMO members and event participants.

Abstract 25P

Background

Circulating tumor DNA (ctDNA) refers to small fragments of DNA, shed from tumor cells into the bloodstream. Measuring it can serve as a non-invasive tool for real-time monitoring of disease dynamics. CtDNA levels have been reported to be predictive of overall survival (OS) in patients with very rare metastastic uveal melanoma (MUM), treated with tebentafusp (Carvajal et el.,2022). Here, we investigate if ctDNA is predictive of progression free survival (PFS) and OS in patients with MUM treated with any therapy.

Methods

Samples from patients treated for MUM at three academic centers were analyzed using a commercially available IVDR-certified digital PCR test. This test includes an integrated analysis software to ensure standardized data analysis across samples and enables the quantification of ctDNA for GNAQ Q209L, GNAQ Q209P and GNA11 Q209L mutations. Patients with at least 2 available samples and clinical data were included.

Results

576 samples from 72 patients with rare MUM were analyzed. 37 patients had GNA11 Q209L, 19 – GNAQ Q209P, and 16 – GNAQ Q209L mutation. 37 patients had baseline samples prior to first-line treatment, 27 of which had detectable levels of ctDNA. Out of 52 patients with baseline samples prior to any line of therapy, 40 had detectable levels. In the first line cohort, non-detectable baseline ctDNA was predictive of better PFS (p = 0.02, and a hazard ratio of 0.28 with p = 0.025) and OS (p = 0.03, and a hazard ratio of 0.14 with p = 0.058). Baseline ctDNA was also predictive for PFS and OS of non first-line therapies (p = 0.03 and p = 0.01).

Conclusions

ctDNA levels have a significant predictive value for PFS and OS in metastatic uveal melanoma, treated with first or subsequent lines of therapy. It provides a non-invasive method to predict outcome.

Legal entity responsible for the study

University Medical Center Hamburg-Eppendorf and University Hospital Zürich.

Funding

Oncobit AG.

Disclosure

J. Kött: Financial Interests, Personal, Speaker’s Bureau, outside the submitted work; BMS, Sanofi, SUN Pharma, Pierre Fabre. S. Freiberger, S. Orjuela: Financial Interests, Personal, Full or part-time Employment: Oncobit AG. R. Dummer: Financial Interests, Personal, Advisory Board, outside the submitted work; Novartis, MSD, BMS, Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi, Catalym, Second Genome, Regeneron, Alligator, T3 Pharma, MaxiVAX SA, Pfizer, Simcere, touchIME. R. Sullivan: Financial Interests, Personal, Research Grant, outside the submitted work; Merck; Financial Interests, Personal, Advisory Board, outside the submitted work; Merck, Marengo, Novartis, Pfizer, Replimune. M.P. Levesque: Financial Interests, Personal, Research Funding, outside the submitted work; Roche, Novartis, Molecular Partners, Scailyte; Financial Interests, Personal, Research Funding: Oncobit. C. Gebhardt: Financial Interests, Personal, Advisory Board, outside the submitted work; Almirall, Amgen, Beiersdorf, BioNTech, BMS, Immunocore, Janssen, MSD, Novartis, Pierre Fabre, Regeneron, Roche, Sanofi, SUN Pharma, Sysmex; Financial Interests, Personal, Research Funding, outside the submitted work; BMS, Novartis, Regeneron, Sanofi. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.